+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Soft Tissue Sarcomas Market by Treatment Type, Histological Subtype, End User, Distribution Channel - Global Forecast to 2030- Product Image
Soft Tissue Sarcomas Market by Treatment Type, Histological Subtype, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Soft Tissue Sarcomas Market by Treatment Type, Histological Subtype, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011940
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Soft Tissue Sarcomas Market grew from USD 730.82 million in 2024 to USD 805.54 million in 2025. It is expected to continue growing at a CAGR of 9.84%, reaching USD 1.28 billion by 2030.

Unveiling the Soft Tissue Sarcoma Landscape

Soft tissue sarcomas represent a diverse group of malignant tumors arising from mesenchymal tissues, encompassing a broad array of subtypes and clinical presentations. As rare but highly heterogeneous malignancies, these cancers pose significant diagnostic and therapeutic challenges. Recent advancements in molecular profiling and immuno-oncology have begun to reshape our understanding of disease mechanisms, yet gaps remain in translating novel discoveries into standardized treatment protocols.

Against this backdrop, healthcare stakeholders-including clinicians, researchers, and industry leaders-seek a comprehensive synthesis of current trends, regulatory developments, and emerging therapeutic modalities. This executive summary distills critical insights from our in-depth market research, offering a clear view of the evolving landscape and strategic imperatives for driving innovation. It highlights key market drivers, identifies pivotal shifts in clinical practice, and underscores opportunities to enhance patient outcomes through targeted interventions and collaborative initiatives.

Emerging Disruptions Reshaping Treatment Paradigms

The treatment paradigm for soft tissue sarcomas is undergoing profound transformation, driven by breakthroughs in targeted therapies and immunotherapy. Conventionally dominated by cytotoxic chemotherapy and surgery, the landscape now incorporates advanced modalities that leverage molecular signatures and immune modulation. Checkpoint inhibitors and adoptive cell therapies are gaining traction, offering durable responses in subsets of patients who historically faced limited options.

Simultaneously, combination therapy regimens are being refined to optimize synergistic effects while mitigating toxicity. Advances in radiation techniques and precision delivery further bolster local control, complementing systemic approaches. Beyond clinical innovations, digital health platforms and real-world evidence networks are accelerating data generation and evidence-based decision-making. These transformative shifts underscore a collective movement toward personalized treatment pathways, marking a new era of precision oncology for patients grappling with soft tissue sarcomas.

Navigating New Tariff Dynamics Impacting the US Market

The introduction of new United States tariffs in 2025 has introduced an additional layer of complexity to the soft tissue sarcoma market. Increased duties on imported active pharmaceutical ingredients and biotechnological components have driven up manufacturing costs, compelling domestic and international manufacturers to reassess supply chain strategies. In response, several companies have diversified their sourcing, relocated production facilities, or renegotiated vendor agreements to maintain margin stability without compromising quality.

These tariff-driven cost dynamics have also influenced pricing negotiations with payers and healthcare institutions, prompting stakeholders to explore value-based contracting models. Manufacturers are intensifying their efforts to demonstrate real-world efficacy and long-term economic impact through robust outcomes data. As a consequence, market participants who proactively adapt to these regulatory and fiscal shifts stand to preserve access and foster sustainable growth in an otherwise challenging environment.

Deep Dive into Market Segmentation Transformations

Segmentation analysis reveals distinct patterns in clinical adoption and revenue distribution across treatment types, histological subtypes, end users, and distribution channels. By treatment type, traditional approaches such as chemotherapy-encompassing alkylating agents, anthracyclines, and taxanes-continue to serve as foundational regimens, while targeted therapies including monoclonal antibodies, mTOR inhibitors, and tyrosine kinase inhibitors are expanding their footprint. Immunotherapy strategies, notably checkpoint inhibitors and adoptive cell therapy, are emerging as critical options in refractory cases. Radical surgery and precision radiation maintain their roles in localized disease control, often integrated into multimodal protocols.

Histological subtype segmentation highlights varied clinical trajectories for entities like liposarcoma and leiomyosarcoma compared with rarer forms such as malignant peripheral nerve sheath tumors. Across end users, hospitals and cancer specialty clinics remain primary care settings for complex sarcoma management, while ambulatory surgical centers and home care settings are gaining prominence for supportive and palliative interventions. Distribution channels are likewise evolving; hospital pharmacies continue to dispense specialized therapies, yet online pharmacies and retail outlets are optimizing patient access to oral regimens and adjunctive medications. Together, these segmentation insights illuminate nuanced market behaviors and inform targeted strategies for product development and commercialization.

Regional Nuances Driving Market Evolution

Regional dynamics play a pivotal role in shaping access, reimbursement, and innovation pathways. In the Americas, robust regulatory frameworks and high healthcare expenditure underpin rapid adoption of advanced therapeutics, though pricing pressures and payer scrutiny remain salient challenges. Collaborative research consortia and clinical trial networks drive continual pipeline development, reinforcing the region's leadership in novel mechanism exploration.

The Europe, Middle East & Africa region exhibits heterogeneous adoption curves, with Western European markets demonstrating early uptake of precision immuno-oncology and Eastern European markets balancing access constraints with emerging reimbursement reforms. Healthcare infrastructure initiatives across the Middle East and selected African countries are catalyzing capacity building, albeit at varying paces. In the Asia-Pacific region, aggressive investments in biotechnology and supportive government policies facilitate local manufacturing of generics and biopharmaceuticals. Simultaneously, growing networks of academic cancer centers fuel patient enrollment in cutting-edge trials, positioning the region as a rising hub for both development and commercialization of sarcoma therapies.

Spotlight on Leading Industry Innovators

A handful of multinational pharmaceutical and biotechnology companies dominate the soft tissue sarcoma market, leveraging deep pipelines and significant R&D investments to drive innovation. These industry leaders excel in advancing candidates through late-stage clinical development, forging partnerships to accelerate combination therapy evaluations, and securing regulatory approvals across multiple jurisdictions. Innovative biotech startups contribute niche expertise in novel modalities such as next-generation adoptive cell therapies and tumor microenvironment modulators, often attracting strategic collaboration and acquisition interest from larger players.

Beyond product pipelines, leading companies differentiate themselves through robust pharmacovigilance programs, patient assistance initiatives, and digital engagement platforms that enhance adherence and quality-of-life monitoring. Strategic alliances between diagnostic firms and therapy developers are also on the rise, as precision medicine approaches demand integrated solutions. Collectively, these competitive strategies underscore an ecosystem momentum geared toward transforming soft tissue sarcoma care by harnessing scientific breakthroughs and optimizing end-to-end patient experiences.

Strategic Roadmap for Industry Advancement

Industry leaders should pursue multifaceted strategies to navigate the evolving soft tissue sarcoma market. First, advancing targeted and immune-based therapies through collaborative clinical trial networks can accelerate patient access and strengthen evidence generation. Aligning trial designs with payer evidence requirements will facilitate market entry and foster reimbursement negotiations. Second, diversifying manufacturing footprints and supply chain partnerships can mitigate tariff-related risks, ensuring consistent drug availability and cost-effectiveness.

Additionally, integrating digital health tools such as remote monitoring and patient-reported outcome platforms can enhance real-world data collection and inform value-based contracting. Strategic investments in emerging markets, supported by localized partnerships and adaptive pricing models, will expand reach and unlock growth potential. Lastly, cultivating cross-sector alliances between biopharma, diagnostics, and technology firms will drive the convergence of precision oncology, enabling earlier detection, monitoring, and personalized therapeutic regimens. By executing these actionable recommendations, organizations can solidify their leadership and contribute to elevating patient care standards.

Robust Methodology Underpinning Our Insights

Our market research methodology combines rigorous secondary research with targeted primary engagements to ensure analytical depth and accuracy. We conducted a comprehensive review of peer-reviewed literature, regulatory submissions, corporate filings, and industry conference proceedings to capture the latest scientific and commercial developments. This desk research was complemented by in-depth interviews with key opinion leaders, including oncologists, pharmacoeconomists, and payer representatives, providing firsthand perspectives on clinical practices, reimbursement dynamics, and investment priorities.

Quantitative analyses leveraged proprietary databases and validated market intelligence tools to track product launches, trial progress, and patent landscapes. Data triangulation techniques were applied to reconcile insights from multiple sources, enhancing reliability. Throughout the process, we adhered to stringent quality protocols, including expert reviews and peer validation, to deliver a robust and transparent foundation for strategic decision-making in the soft tissue sarcoma domain.

Synthesis of Key Findings and Market Outlook

This executive summary synthesizes the critical themes shaping the soft tissue sarcoma market, from disruptive therapeutic innovations to complex regulatory and economic forces. Key takeaways include the pivotal role of precision and immune-based therapies in redefining treatment paradigms, the urgent need for supply chain resilience amid evolving tariff landscapes, and the strategic importance of integrated partnerships spanning diagnostics, digital health, and biopharma.

Regional analyses reveal differentiated growth trajectories, underscoring the necessity of tailored market entry and expansion strategies. Segmentation insights highlight where therapeutic and operational focus can yield the greatest impact, while competitive intelligence exposes best practices for sustaining R&D momentum. As stakeholders navigate this dynamic environment, the convergence of scientific innovation, real-world evidence, and stakeholder collaboration will determine the speed at which patient needs are met and long-term value is created.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
      • Alkylating Agents
      • Anthracyclines
      • Taxanes
    • Combination Therapy
    • Immunotherapy
      • Adoptive Cell Therapy
      • Checkpoint Inhibitors
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
      • Monoclonal Antibodies
      • mTOR Inhibitors
      • Tyrosine Kinase Inhibitors
  • Histological Subtype
    • Fibrosarcoma
    • Leiomyosarcoma
    • Liposarcoma
    • Malignant Peripheral Nerve Sheath Tumor
    • Synovial Sarcoma
    • Undifferentiated Pleomorphic Sarcoma
  • End User
    • Ambulatory Surgical Centers
    • Cancer Specialty Clinics
    • Home Care Settings
    • Hospitals
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacy
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Eisai Co., Ltd.
  • Janssen Pharmaceutica NV
  • Pfizer Inc.
  • PharmaMar, S.A.
  • Bayer AG
  • Eli Lilly and Company
  • Adaptimmune Therapeutics plc
  • Deciphera Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Soft Tissue Sarcomas Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Alkylating Agents
8.2.2. Anthracyclines
8.2.3. Taxanes
8.3. Combination Therapy
8.4. Immunotherapy
8.4.1. Adoptive Cell Therapy
8.4.2. Checkpoint Inhibitors
8.5. Radiation Therapy
8.6. Surgery
8.7. Targeted Therapy
8.7.1. Monoclonal Antibodies
8.7.2. mTOR Inhibitors
8.7.3. Tyrosine Kinase Inhibitors
9. Soft Tissue Sarcomas Market, by Histological Subtype
9.1. Introduction
9.2. Fibrosarcoma
9.3. Leiomyosarcoma
9.4. Liposarcoma
9.5. Malignant Peripheral Nerve Sheath Tumor
9.6. Synovial Sarcoma
9.7. Undifferentiated Pleomorphic Sarcoma
10. Soft Tissue Sarcomas Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Cancer Specialty Clinics
10.4. Home Care Settings
10.5. Hospitals
11. Soft Tissue Sarcomas Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacy
11.4. Retail Pharmacies
12. Americas Soft Tissue Sarcomas Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Soft Tissue Sarcomas Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Soft Tissue Sarcomas Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Eisai Co., Ltd.
15.3.2. Janssen Pharmaceutica NV
15.3.3. Pfizer Inc.
15.3.4. PharmaMar, S.A.
15.3.5. Bayer AG
15.3.6. Eli Lilly and Company
15.3.7. Adaptimmune Therapeutics plc
15.3.8. Deciphera Pharmaceuticals, Inc.
15.3.9. Merck KGaA
15.3.10. Novartis AG
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. SOFT TISSUE SARCOMAS MARKET MULTI-CURRENCY
FIGURE 2. SOFT TISSUE SARCOMAS MARKET MULTI-LANGUAGE
FIGURE 3. SOFT TISSUE SARCOMAS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SOFT TISSUE SARCOMAS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TAXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY FIBROSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY MALIGNANT PERIPHERAL NERVE SHEATH TUMOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY SYNOVIAL SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY UNDIFFERENTIATED PLEOMORPHIC SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY CANCER SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SOFT TISSUE SARCOMAS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SOFT TISSUE SARCOMAS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 57. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 60. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. CANADA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 67. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. MEXICO SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 103. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. GERMANY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 108. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 110. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. FRANCE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 124. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 125. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. ITALY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SPAIN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 145. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 159. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 160. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. DENMARK SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 169. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 173. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 174. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. QATAR SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 178. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 179. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 181. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. FINLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 198. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 199. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 201. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 202. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. EGYPT SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 205. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 207. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 208. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 209. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. TURKEY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 222. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 223. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. NORWAY SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 227. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 228. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 229. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 230. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. POLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 236. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 237. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC SOFT TISSUE SARCOMAS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 247. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 248. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 249. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 251. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 252. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. CHINA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 258. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 259. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. INDIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 263. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 264. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 265. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. JAPAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 291. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 292. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 293. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 294. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. THAILAND SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 300. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 301. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. PHILIPPINES SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 307. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 308. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 309. MALAYSIA SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 313. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 314. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 315. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. SINGAPORE SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 319. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 321. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 322. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 323. VIETNAM SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 324. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 325. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 326. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 327. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 328. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY HISTOLOGICAL SUBTYPE, 2018-2030 (USD MILLION)
TABLE 329. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. TAIWAN SOFT TISSUE SARCOMAS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 331. SOFT TISSUE SARCOMAS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 332. SOFT TISSUE SARCOMAS MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Soft Tissue Sarcomas market report include:
  • Eisai Co., Ltd.
  • Janssen Pharmaceutica NV
  • Pfizer Inc.
  • PharmaMar, S.A.
  • Bayer AG
  • Eli Lilly and Company
  • Adaptimmune Therapeutics plc
  • Deciphera Pharmaceuticals, Inc.
  • Merck KGaA
  • Novartis AG

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 805.54 Million
Forecasted Market Value ( USD ) by 2030 $ 1280 Million
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Kaposi Sarcoma Market by Patient Population, Treatment Modality, Disease Type, Distribution Site, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Kaposi Sarcoma Market by Patient Population, Treatment Modality, Disease Type, Distribution Site, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Sarcoma Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Sarcoma Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Kaposi Sarcoma - Global Strategic Business Report - Product Image

Kaposi Sarcoma - Global Strategic Business Report

  • Report
  • 309 Pages
  • Global
From
Cancers in the Urban Environment. How Malignant Diseases Are Caused and Distributed among the Diverse People and Neighborhoods of a Major Global Metropolis. Edition No. 2 - Product Image

Cancers in the Urban Environment. How Malignant Diseases Are Caused and Distributed among the Diverse People and Neighborhoods of a Major Global Metropolis. Edition No. 2

  • Book
  • Global
Ewings Sarcoma Treatment Market 2025-2029 - Product Image

Ewings Sarcoma Treatment Market 2025-2029

  • Report
  • 197 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.